Streetbeat News

Regulatory

MU

Micron Technology (MU) is uncertain whether systems built for export will be subject to CDC restrictions, according to a Reuters report.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:36 pm

BABA

JD

NTES

PDD

Chinese stocks are trading higher after the Chinese government announced that interest rates would remain unchanged.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:33 pm

FXI

China's gaming regulator has granted approval for 86 domestic online games in May, including titles from Tencent and NetEase. This comes after a nine-month freeze on approvals in 2018.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:32 pm

FRLN

Freeline Therapeutics' shares are trading higher after the company received ILAP designation in the U.K. by MHRA for LFT201.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:23 pm

FXI

MU

Micron Technology received a notice from the Cyberspace Administration of China (CAC) stating that its products present a cybersecurity risk. The CAC has advised critical information infrastructure operators in China to stop using Micron products.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:21 pm

NARI

Inari Medical announces the PEERLESS II randomized controlled trial to evaluate the clinical outcomes of its FlowTriever System compared to anticoagulation in pulmonary embolism patients.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:20 pm

PIRS

Pieris Pharmaceuticals presented encouraging preclinical data for PRS-400, an inhaled therapy for muco-obstructive lung diseases, at the ATS 2023 International Conference. The data showed that PRS-400 reached desired potency goals and demonstrated in vivo proof of concept. PRS-400 is expected to advance to clinical development later this year.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:17 pm

FXI

MU

Micron Technology is cooperating with the Cybersecurity Administration of China and working to understand the details of their security concerns.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:14 pm

KRYS

The FDA has approved Krystal Biotech's Vyjuvek, the first-ever redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). Vyjuvek is expected to be available in the US in Q3 2023. Krystal Biotech has also announced a private placement of 1.73 million shares at $92.50, raising approximately $160 million.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 12:10 pm

SGMO

Sangamo Therapeutics has received Fast Track Designation from the U.S. FDA for its gene therapy product candidate, isaralgagene civaparvovec (ST-920), for the treatment of Fabry disease. The designation aims to expedite the development and review of new therapeutics for serious conditions with unmet medical needs.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:09 pm